Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.
The success of the mRNA vaccines for COVID-19 led to explosive growth in lipid nanoparticle (LNP)-mediated drug delivery for RNA vaccines and therapeutics. As these projects scale into clinical trials ...
Product Performance – potency and dosing: Cryogenic transmission electron microscopy (Cryo-TEM) revealed more uniform, solid-core particles. Increased lipid and RNA concentrations can enhance in vivo ...
ASPIRO is the first multi-patient, multi-center clinical trial of an autologous cell therapy for Parkinson's disease. It is evaluating safety, tolerability, and preliminary efficacy of ANPD001 in ...
Global Pharmaceutical Manufacturing Equipment Market OverviewThe global pharmaceutical manufacturing equipment market is on a growth trajectory, projected to expand at a CAGR of 6–8% over the forecast ...
The "Fill Finish Manufacturing Market - A Global and Regional Analysis: Focus on Product, End Users, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical's HLA-G targeted exosome ...
Depending on whom you ask, we are either in the early stages of, somewhat immersed in, or already fully immersed in Industry 4.0, the fourth industrial revolution. Industry 4.0 incorporates artificial ...
SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...
According to MarketsandMarkets™, the Human Microbiome Drugs Market is projected to grow from about USD 0.35 billion in 2025 to USD 2.13 billion by 2031, at a CAGR of 35.2%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback